Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI)

Tumori

Volumn 82, Issue 6, 1996, Pages 554-559

  Ribas, Antoni ^a,b   Bellmunt, Joaquim ^a   Albanell, Joan ^a   De Torres, Inés ^a   Bermejo, Begoña ^a   De Torres, Jose A ^a   Morote, Joan ^a   Gallardo, Enrique ^a   Vera, Ruth ^a   Carulla, Joan ^a   Sole Calvo, Luis Alfonso ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bladder cancer; carboplatin; immunohistochemistry; p53

Indexed keywords

CARBOPLATIN; METHOTREXATE; PROTEIN P53; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PROGNOSIS;

EID: 12644318765     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169608200608     Document Type: Article

References (37)

1. Allred D.C., Clark G.M., Tandon A.K., Molina R., Tormey D.C., Osborne C.K., Gilchrist K.W., Mansour E.G., Abeloff M., Eudey L., McGuire W.L.: HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10: 599-605, 1992.
2. Badalament R.A.: (Editorial) Transitional cell carcinoma: a common sense approach. J. Urol., 153: 61-62, 1995.
3. Banks L., Matlashewski G., Crawford L.: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159: 529-534, 1986.
4. Bellmunt J., Albanell J., Gallego O.S., Ribas A., Vicente P., Carulla J., De Torres J.A., Morote J., Lopez M., Solé L.A.: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer, 70: 1974-1979, 1992.
5. Bellmunt J., Ribas A., Albanell J., De Torres I., Bermejo B., De Torres J.A., Morote J., López-Pacios M.A., Banús Gassol J.M., Casado S., Carulla J., Solé L.A.: M-CAVI: a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Am. J. Clin. Oncol., 19: 344-348, 1996.
6. Bergkvist A., Ljunguist A., Moberger G.: Classification of bladder tumors based on the cellular pattern. Acta Chir. Scand., 130: 371-378, 1965.
7. Calvert A.H., Newell D.R., Grumbell L.A., O'Reilly S., Brunell M.C., Boxall F.E., Siddik A.M., Judson I.R., Gore M.E., Wiltshaw E.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
8. Cordon-Cardo C., Dalbagni G., Saez G.R., Oliva M.R., Zhang Z.F., Rosai J., Reuter V.E., Pellicer A.: p53 mutations in human bladder cancer: genotypic versus phenotipic patterns. Int. J. Cancer., 56: 347-353, 1994.
9. Cox D.R.: Partial likelihood. Biometrika, 62: 269-279, 1975.
10. Esrig D., Elmajian D., Groshen S., Freeman J.A., Stein J.P., Chen S.C., Nichols P.W., Skinner D.G., Jones P.A., Cote R.J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
11. Esrig D., Spruch C.H., Nichols P.W., Chaiwun B., Steven K., Groshen S., Chen S.C., Skinner D.G., Jones P.A., Cote R.J.: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389-1397, 1993.
12. Fossa S.D., Brener A.A., Jacobsen A-B., Waehre H., Kvarstein B., Urnes T., Ogreid P., Bjerklund Johansen T.E., Slide J., Nesland J.M., Pettersen E.O.: Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer. Br. J. Cancer, 68: 572-578, 1993.
13. Fujimoto K., Yamada Y., Okajima E., Kakizoe T., Sasaki H., Sugimura T., Terada M.: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393-1398, 1992.
14. Furihata M., Inoue K., Ohtsuki Y., Hashimoto H., Terao N., Fujita Y.: High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res., 53: 4823-4827, 1993.
15. Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam M., Golouh R., Reed R., Martinez-Tello F., Tiltman A., Thorhorst J., Grigolato P., Bettelheim R., Neville A.M., Castiglione M., Collins J., Lindtner J., Senn H.J.: Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1056, 1992.
16. Harris A.L.: Mutant p53. The commonest genetic abnormality in human cancer? J. Pathol., 162: 5-6, 1990.
17. Lipponen P.K.: Expression of nuclear oncoprotein p53 in transitional cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365-370. 1993.
18. Lipponen P., Eskelinen M.: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer, 69: 1120-1125, 1994.
19. Moch H., Sauter G., Moore D., Mihatsch M.J., Gudat F., Waldman F.: p53 and erbB-2 protein overexpression are associated with early invasion and metastases in bladder cancer. Virchows Archiv. [Pathol. Anat.], 423: 329-334, 1993.
20. Muss H.B., Thor A.D., Berry D.A., Kute T., Liu E.T., Koerner F., Cirrincione C.T., Budman D.R., Wood W.C., Barcos M., Henderson I.C.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1993.
21. Olumi A.F., Tsai Y.C., Nichols P.W., Skinner D.G., Cain D.R., Bender L.I., Jones P.A.: Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res., 50: 7081-7083, 1990.
22. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., Smith P.G.: Design and analysis of randomized trials requiring prolonged observation of each patient. II. Br. J. Cancer, 35: 1-35, 1977.
23. Presti J.C., Reuter T.G., Fair W.R., Cordon-Cardo C.: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res., 51: 5405-5409, 1991.
24. Sarkis A.S., Bajorin D.F., Reuter V.E., Herr H.W., Netto G., Zhang Z.F., Schultz P.K., Cordon-Cardo C., Scher H.: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M-VAC. J. Clin. Oncol., 13: 1384-1390, 1995.
25. Sarkis A.S., Cordon-Cardo C., Reuter V.R., Herr H.W., Zhang Z-F., Melamed J., Schultz P., Barjorin D., Fair W.R., Scher H.I.: p53 overexpression in patients with invasive bladder cancer treated with neoadjuvant methotrexate, vinblastine, adriamycin, and cisplatin (M-VAC). Proc. Am. Soc. Clin. Oncol., 12: 249, 1993.
26. Sarkis A.S., Dalbagni G., Cordon-Cardo C., Melamed J., Zhang Z.F., Sheinfeld J., Fair W.R., Herr H.W., Reuter V.E.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152: 388-392, 1994.
27. Sarkis A.S., Dalbagni G., Cordon-Cardo C., Zhang Z.F., Sheinfeld J., Fair W.R., Herr H.W., Reuter V.E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53-59, 1993.
28. Scher H.I.: Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Semin. Oncol., 17: 555-565, 1990.
29. Schultz P., Herr H.W., Zhang Z.F., Bajorin D.F., Seidman A.D., Sarkis A.S., Fair W.R., Scherr D., Bosl G.J., Scher H.I.: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J. Clin. Oncol., 12: 1394-1401, 1994.
30. Sidransky D., Von Eschenbach A., Tsai Y.C., Jones P.A., Summerhayes I., Marshall F., Paul M., Green P., Hamilton S.R., Frost P., Volgelstein B.: Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252: 706-709, 1991.
31. Skinner D.G., Daniels J.R., Russell C.A., Lieskovsky G., Boyd S.D., Nichols P., Kern W., Sakamoto J., Krailo M., Groshen S.: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145: 459-467, 1991.
32. Soloway M.S.: Selecting initial therapy for bladder cancer. Cancer, 60: 502-513, 1987.
33. Splinter T.A.W., Pavone-Macaluso P., Jacqmin D., Roberts J.T., Carpentier P., De Pauw M., Sylvester R.: A European Organization for Research and Treatment of Cancer-Genito-urinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response. J. Urol., 148: 1793-1796, 1992.
34. Stöckle M., Meyenburg W., Wellek S., Voges G., Gertenbach U., Thüroff J.W., Huber C.H., Hohenfellner R.: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: results of a controlled prospective study. J. Urol., 148: 302-307, 1992.
35. Stöckle M., Meyenburg W., Wellek S., Voges G.E., Rossmann M., Gertenbach U., Thüroff J.W., Huber C., Hohenfellner R.: Adjuvant polychemotherapy of nonoigan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol., 153: 47-52, 1995.
36. Vet J.A., Bringuer P.P., Poddighe P.J., Karthaus H.F., Debruyne F.M., Schalken J.A.: p53 mutations have no additional prognostic value over stage in bladder cancer. Br. J. Cancer, 70: 496-500, 1994.
37. Wright C., Mellon K., Johnston P., Lane D.P., Harris A.L., Home C.H.W, Neal D.E.: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer, 63: 967-970, 1991.